
-
India's gaming fans eye illegal sites after gambling ban
-
EU business lobby head says China rare earths snag persists
-
Botox under burqas: Cosmetic surgery in vogue in Afghanistan
-
Asian stocks swing as traders bide time ahead of US rate decision
-
Australia, Papua New Guinea delay mutual defence treaty
-
PGA's 2026 opener will not be played at drought-hit Kapalua
-
Toucans, tortoises saved in major Brazil trafficking bust
-
Britain rolls out royal red carpet for Trump's state visit
-
US Fed set for first rate cut of 2025 as Trump pressure looms
-
Broadway jeering Caesars Times Square casino bet
-
Rojas, McLaughlin-Levrone go for gold at world champs
-
Colombian FARC leaders ordered to make reparations for over 21,000 kidnappings
-
Kirk suspect faces death penalty for aggravated murder charge
-
Peru evacuates 1,400 tourists from Machu Picchu amid protest
-
Trump arrives in UK for historic second state visit
-
Arsenal, Real Madrid win Champions League openers, Juve snatch dramatic draw
-
Friends like these: NY to get 'Central Perk' cafe from beloved sitcom
-
Mbappe penalty double gives Real Madrid opening win over Marseille
-
Windsor poised for global spotlight with Trump state visit
-
Juve salvage point against Dortmund with stunning late comeback
-
Redford's Sundance legacy hailed by filmmakers
-
Spurs accept Villarreal gift to make winning start in Champions League
-
Trump arrives in Britain for unprecedented second state visit
-
FBI chief spars with Democrats in heated Senate hearing
-
'A better future is possible': Youths sue Trump over climate change
-
Redford's Sundance legacy 'beyond comprehension' for US filmmakers
-
Vuelta protests 'a completely new phenomenon', says Tour de France director
-
Bangladesh beat Afghanistan to stay alive in Asia Cup
-
Trump extends delay on US TikTok ban until mid-December
-
YouTube ramps up AI tools for video makers
-
Arsenal subs snatch win in Bilbao Champions League opener
-
Downton Abbey auction of props and costumes smashes estimates
-
Windsor prepares for global spotlight with Trump state visit
-
Suspect in Charlie Kirk killing charged with murder
-
France duo out of Women's Rugby World Cup semi-final as bans upheld
-
Simeone backs Atletico to hurt 'extraordinary' Liverpool
-
IEA says more oil and gas investment may be needed
-
Sabrina Carpenter, Justin Bieber, Karol G to headline Coachella
-
Colombia halts US arms purchases in row over drug fight delisting
-
Nestle says chairman Paul Bulcke to step down
-
Isak set for Liverpool debut in Atletico Madrid Champions League clash
-
Malawi votes in economic gloom as two presidents battle for power
-
No info in files that Epstein trafficked women to others: FBI chief
-
Stocks slip, dollar down as Fed meets on rates
-
Faith Kipyegon: Supreme Kenyan champion and role model for mothers
-
Hollywood giants sue Chinese AI firm over copyright infringement
-
Bayern's Kane keen to rekindle London rivalry against Chelsea
-
Trump sues NYT for $15 bn in latest attack on media
-
IndyCar reveals 17-race 2026 season with March opening
-
Trump heads for landmark state visit with 'friend' King Charles
CMSC | 0.29% | 24.39 | $ | |
RBGPF | 0% | 77.27 | $ | |
CMSD | 0.04% | 24.46 | $ | |
NGG | -1.04% | 70.88 | $ | |
RYCEF | -0.06% | 15.64 | $ | |
GSK | -0.62% | 40.05 | $ | |
VOD | -0.34% | 11.77 | $ | |
SCS | 0.06% | 16.88 | $ | |
RELX | -0.36% | 46.69 | $ | |
JRI | -1.01% | 13.92 | $ | |
AZN | -0.63% | 77.56 | $ | |
BCC | -3.31% | 82.39 | $ | |
BP | 0.64% | 34.43 | $ | |
RIO | -0.44% | 63.44 | $ | |
BCE | -1.11% | 23.43 | $ | |
BTI | -0.43% | 55.79 | $ |

Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
O.Norris--AMWN